|
Synonyms: FE 999301 | FE-301 | FE-999301 | TJ301
Compound class:
Peptide or derivative
Comment: Olamkicept is a recombinant protein that fuses the extracellular domain of the signal transducing subunit of the IL-6 receptor, IL-6Rβ (glycoprotein 130, gp130), to a human IgG Fc fragment [3]. The full construct is a dimer of covalently linked identical peptide chains. Mechanistically olamkicept acts as an inhibitor of the IL-6 signalling pathway. Olamkicept inhibits trans signalling by the soluble IL-6 receptor (sIL-6R) [1], a mechanism that is involved in human inflammatory and autoimmune diseases [2]. It is hypothesised to be clinically effective in reducing disease signs and symptoms whilst not being detrimental to the role of IL-6 in the acute immune response to infection.
|
| Immunopharmacology Comments |
| Olamkicept is a selective inhibitor of the IL-6 proinflammatory pathway. It blocks trans signaling that occurs via the soluble IL-6R (sIL-6R) and this action is effective against Crohn's disease and experimental colitis in vivo [1]. |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Ulcerative colitis |
Disease Ontology:
DOID:8577 OMIM: 266600 Orphanet: ORPHA771 |
Phase 2 clinical candidate for active UC- see NCT03235752. | |
